Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 832

The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Open access
Vogelbaum, Michael A., Brown, Paul D., Messersmith, Hans, Brastianos, Priscilla K., Burri, Stuart, Cahill, Dan, Dunn, Ian F., Gaspar, Laurie E., Gatson, Na Tosha N., Gondi, Vinai, Jordan, Justin T., Lassman, Andrew B., Maues, Julia, Mohile, Nimish, Redjal, Navid, Stevens, Glen, Sulman, Erik, van den Bent, Martin, Wallace, H. James, Weinberg, Jeffrey S., Zadeh, Gelareh, Schiff, David·2022·Journal of Clinical Oncology

Abstract

PURPOSE: To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS: Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. RECOMMENDATIONS: Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non–small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.02314

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 147 references

Cited by

See all 832

Metadata

Authors
Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., Jordan, J. T., Lassman, A. B., Maues, J., Mohile, N., Redjal, N., Stevens, G., Sulman, E., van den Bent, M., Wallace, H. J., Weinberg, J. S., Zadeh, G., & Schiff, D.
Venue
Journal of Clinical Oncology
Published
2022-02-10
Volume
40
Issue
5
Pages
492-516
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4200190043
Cited by
832
References
147
FWCI
64.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. https://app.cochat.ai/papers/10.1200/jco.21.02314
The paper
Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., Jordan, J. T., Lassman, A. B., Maues, J., Mohile, N., Redjal, N., Stevens, G., Sulman, E., van den Bent, M., Wallace, H. J., . . . Schiff, D. (2022). Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.02314

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.